S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.